278 related articles for article (PubMed ID: 27877214)
1. Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis.
Altobelli E; Angeletti PM; Latella G
J Cancer; 2016; 7(14):1984-2004. PubMed ID: 27877214
[TBL] [Abstract][Full Text] [Related]
2. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
3. Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis.
van Liere ELSA; van Dijk LJ; Bosch S; Vermeulen L; Heymans MW; Burchell GL; de Meij TGJ; Ramsoekh D; de Boer NKH
Eur J Cancer; 2023 Jun; 186():69-82. PubMed ID: 37030079
[TBL] [Abstract][Full Text] [Related]
4. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia.
Johnson JC; Schmidt CR; Shrubsole MJ; Billheimer DD; Joshi PR; Morrow JD; Heslin MJ; Washington MK; Ness RM; Zheng W; Schwartz DA; Coffey RJ; Beauchamp RD; Merchant NB
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1358-65. PubMed ID: 16996805
[TBL] [Abstract][Full Text] [Related]
5. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
Nasir Kansestani A; Zare ME; Tong Q; Zhang J
Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
[TBL] [Abstract][Full Text] [Related]
6. Diacetylated derivatives of spermine and spermidine as novel promising tumor markers.
Kawakita M; Hiramatsu K
J Biochem; 2006 Mar; 139(3):315-22. PubMed ID: 16567395
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of faecal
Wong SH; Kwong TNY; Chow TC; Luk AKC; Dai RZW; Nakatsu G; Lam TYT; Zhang L; Wu JCY; Chan FKL; Ng SSM; Wong MCS; Ng SC; Wu WKK; Yu J; Sung JJY
Gut; 2017 Aug; 66(8):1441-1448. PubMed ID: 27797940
[TBL] [Abstract][Full Text] [Related]
8. Screening for colon cancer: A test for occult blood.
Khakimov N; Khasanova G; Ershova K; Gibadullina L; Vetkina T; Lobisheva G; Chumakova A
Int J Risk Saf Med; 2015; 27 Suppl 1():S110-1. PubMed ID: 26639687
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma.
Liu R; Su X; Long Y; Zhou D; Zhang X; Ye Z; Ma J; Tang T; Wang F; He C
Mutat Res Rev Mutat Res; 2019; 779():45-57. PubMed ID: 31097151
[TBL] [Abstract][Full Text] [Related]
10. Determination of amounts of polyamines excreted in urine: demonstration of N1,N8-diacetylspermidine and N1,N12-diacetylspermine as components commonly occurring in normal human urine.
Hiramatsu K; Sugimoto M; Kamei S; Hoshino M; Kinoshita K; Iwasaki K; Kawakita M
J Biochem; 1995 Jan; 117(1):107-12. PubMed ID: 7775374
[TBL] [Abstract][Full Text] [Related]
11. Altered Polyamine Profiles in Colorectal Cancer.
Venäläinen MK; Roine AN; Häkkinen MR; Vepsäläinen JJ; Kumpulainen PS; Kiviniemi MS; Lehtimäki T; Oksala NK; Rantanen TK
Anticancer Res; 2018 Jun; 38(6):3601-3607. PubMed ID: 29848716
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of urinary diacetylpolyamines as novel tumor markers].
Kawakita M; Hiramatsu K; Sugimoto M; Takahashi K; Toi M
Rinsho Byori; 2004 Apr; 52(4):321-7. PubMed ID: 15164599
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers.
Umemori Y; Ohe Y; Kuribayashi K; Tsuji N; Nishidate T; Kameshima H; Hirata K; Watanabe N
Clin Chim Acta; 2010 Dec; 411(23-24):1894-9. PubMed ID: 20655890
[TBL] [Abstract][Full Text] [Related]
14. Combined Plasma MicroRNA and Fecal Occult Blood Tests in Early Detection of Colorectal Cancer.
Luo X; Wu Y; Ji M; Zhang S
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115212
[TBL] [Abstract][Full Text] [Related]
15. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma.
Shrubsole MJ; Cai Q; Wen W; Milne G; Smalley WE; Chen Z; Ness RM; Zheng W
Cancer Prev Res (Phila); 2012 Feb; 5(2):336-42. PubMed ID: 22166248
[TBL] [Abstract][Full Text] [Related]
16. A novel faecal
Liang JQ; Li T; Nakatsu G; Chen YX; Yau TO; Chu E; Wong S; Szeto CH; Ng SC; Chan FKL; Fang JY; Sung JJY; Yu J
Gut; 2020 Jul; 69(7):1248-1257. PubMed ID: 31776231
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single-centre bowel screening population (UK BCSP).
Mozdiak E; Wicaksono AN; Covington JA; Arasaradnam RP
Tech Coloproctol; 2019 Apr; 23(4):343-351. PubMed ID: 30989415
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of colorectal tumours in asymptomatic patients with negative immunochemical faecal occult blood test results.
Wakamura K; Kudo SE; Miyachi H; Kodama K; Hayashi S; Maeda Y; Ogawa Y; Kouyama Y; Kataoka SI; Kato K; Ichimasa K; Misawa M; Mori Y; Kudo T; Hayashi T; Ishida F; Ohkoshi S
Mol Clin Oncol; 2015 Sep; 3(5):1019-1024. PubMed ID: 26623043
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk.
Davenport JR; Cai Q; Ness RM; Milne G; Zhao Z; Smalley WE; Zheng W; Shrubsole MJ
Mol Carcinog; 2016 Aug; 55(8):1251-61. PubMed ID: 26333108
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
